, Volume 60, Issue 12, pp 2538–2539 | Cite as

Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]



Bladder cancer Empagliflozin SGLT2 inhibitors 



Food and Drug Administration


Sodium–glucose cotransporter 2


  1. 1.
    Shaikh AMY (2017) SGLT2 inhibitors and cancer: why further evidence is required. Diabetologia https://doi.org/10.1007/s00125-017-4434-9
  2. 2.
    Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128CrossRefPubMedGoogle Scholar
  3. 3.
    Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J (2017) SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia https://doi.org/10.1007/s00125-017-4370-8
  4. 4.
    US Food and Drug Administration (2007) Food and Drug Administration Amendments Act of 2007. Public Law 110-85. Available from www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf. Accessed 12 August 2017
  5. 5.
    Kohler S, Lee J, George JT, Inzucchi SE, Zinman B (2017) Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia https://doi.org/10.1007/s00125-017-4430-0

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of Epidemiology, Richard M. Fairbanks School of Public HealthIndiana UniversityIndianapolisUSA
  2. 2.Melvin and Bren Simon Cancer CenterIndiana UniversityIndianapolisUSA

Personalised recommendations